On the stock market since 1995, it operates in the world of health and science. It has 952 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 54% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 39% — that slice of every sale is the company’s cushion in hard quarters.
There is $735.1M in the vault; even if every debt were paid off, $486.3M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 3 years, sales fell about 11% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, NVAX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NVAX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.